体重指数与身高对胶质母细胞瘤及其他胶质瘤亚组风险的影响:一项大型前瞻性队列研究
超重和肥胖与任何胶质瘤亚组风险均无关;身高与胶质母细胞瘤及所有其他胶质瘤风险呈正相关,但与IDH突变型胶质瘤的替代指标无关。作者认为该研究巩固了身高作为胶质母细胞瘤和其他胶质瘤危险因素的地位,并提示这种关联在不同胶质瘤亚组间可能不同。
要点
- 超重和肥胖与任何胶质瘤亚组风险均无关。
- 身高每增加10 cm,胶质母细胞瘤风险HR 1.24(95%CI 1.17-1.31),所有其他胶质瘤HR 1.18(95%CI 1.09-1.29)。
- 身高与IDH突变型胶质瘤替代指标无关(HR 1.09;95%CI 0.98-1.21)。
核心结论
- 该流行病学研究巩固了身高作为胶质母细胞瘤和其他胶质瘤危险因素的地位,并进一步提示这种关联并非普遍适用于所有胶质瘤,可能在不同胶质瘤亚组间存在差异。
主要发现
- 超重和肥胖与任何胶质瘤亚组风险均无关。
- 身高与胶质母细胞瘤风险呈正相关(每增加10 cm的HR 1.24;95%CI 1.17-1.31),与所有其他胶质瘤风险也呈正相关(HR 1.18;95%CI 1.09-1.29)。
- 身高与IDH突变型胶质瘤的替代指标无关(HR 1.09;95%CI 0.98-1.21)。
- 进一步亚组分析中,身高对胶质瘤风险的影响存在显著差异:少突星形细胞瘤呈正相关(HR 1.74;95%CI 1.20-2.53),恶性胶质瘤未另作说明(NOS)呈正相关(HR 1.42;95%CI 1.16-1.76),但与弥漫性星形细胞瘤(WHO II级和III级)或少突胶质细胞瘤无关。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Glioma comprises a heterogeneous group of mostly malignant brain tumors, whereof glioblastoma (GBM) represents the largest and most lethal subgroup. Body height and body mass index (BMI) are risk factors for other cancers, but no previous study has examined anthropometric data in relation to different glioma subgroups. METHODS: This prospective cohort study includes 1.8 million Norwegian women and men between ages 14 and 80 years at baseline. Body weight and height were measured, and incident cases of glioma were identified by linkage to the National Cancer Registry. Cox regression analyses were performed to evaluate risk for different glioma subgroups in relation to anthropometric measures. RESULTS: During 54 million person-years of follow-up, 4,382 gliomas were identified. Overweight and obesity were not associated with risk for any glioma subgroup. Height was positively associated with risk for GBM and all other gliomas (hazard ratio [HR] per 10 cm increase: 1.24; 95% confidence interval [CI], 1.17-1.31 and 1.18; 95% CI, 1.09-1.29) but not with the proxy for isocitrate dehydrogenase (IDH)-mutant glioma (HR, 1.09; 95% CI, 0.98-1.21). In further subgroup analyses, the effect of height on glioma risk varied significantly with positive associations for oligoastrocytoma (HR, 1.74; 95% CI, 1.20-2.53) and malignant glioma not otherwise specified (NOS) (HR, 1.42; 95% CI, 1.16-1.76, but not with diffuse astrocytoma (WHO grades II and III) or oligodendroglioma. CONCLUSION: This epidemiologic study consolidates height as a risk factor for GBM and other gliomas. It further indicates that this association is not universal for gliomas but may differ between different glioma subgroups.
引用
- Wiedmann MKH, Brunborg C, Di Ieva A, et al. The impact of body mass index and height on the risk for glioblastoma and other glioma subgroups: a large prospective cohort study. Neuro Oncol. 2017. PMID: 28040713. doi:10.1093/neuonc/now272
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。